Denali Therapeutics
DNLI
18.45
+0.25
+1.37%
Denali Therapeutics
US · DNLI
#2454 by market cap
Listed 2017
18.45
+0.25
+1.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
About Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
- Founded
- 2013
- CEO
- Dr. Ryan J. Watts, PhD
- Employees
- 503
- Headquarters
- San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- denalitherapeutics.com
Company profile
- Exchange
- US
- Symbol
- DNLI
- Market-cap rank
- #2454
- Listing date
- 2017-12-08
- Market cap
- 2.96B
- Float cap
- 2.87B
- Shares out
- 160.29M
- Float shares
- 155.54M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Denali Therapeutics discussion 0 comments